An observational study in Lung Cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences — 10 open to participants now, 11 under way, none of them phase 3. Lung Neoplasms · Cancer Institute and Hospital, Chinese Academy of Medical Sciences.
Among the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, this one is one of 2 that started in 2024, is one of 6 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 12th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →10 of the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences are open now, in 1 country. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages up to 99
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 200 across 1,436 observational studies indexed under Lung Neoplasms.
Median enrollment 80 across the 13 interventional studies, 15,000 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences is the lead sponsor of 396 studies on the registry; 281 are open to participants now.
4 of the studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904015Cancer Institute and Hospital, Chinese Academy of Medical SciencesThe Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC | 2026-12-30 |
| NCT07596524Cancer Institute and Hospital, Chinese Academy of Medical SciencesAnalysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy | 2026-12-31 |
| NCT06928922Cancer Institute and Hospital, Chinese Academy of Medical SciencesmRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors | 2027-02-24 |
| NCT05886439Cancer Institute and Hospital, Chinese Academy of Medical SciencesLK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer | 2027-05-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Lung Neoplasms by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of early-stage lung cancer patients who have received surgery using the real-world data. The main questions it aims to answer are:
This observational study aims to comprehensively evaluate the effectiveness and long-term clinical outcomes of surgical interventions in early-stage lung cancer patients, utilizing real-world data.
Central to this investigation are two key questions:
Patients with lung cancer who have received surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group have received Sublobar resection.
Other: Sublobar resection
Patients in this group have received lobectomy.
Other: Lobectomy
Sublobar resection is a series of surgical approaches for lung cancer.
Lobectomy is the surgical approach for lung cancer.
Disease-free survival(DFS)
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
Time frame: Defined as the time from the date of surgery until the date of first documented progression or death (by any cause in the absence of recurrence), whichever came first, assessed up to 10 years.
Overall Survival (OS)
OS is defined as the time from surgery time until death from any cause.
Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 10 years.
5-year Overall Survival (overall survival) Rate
The time from surgery time until death from any cause, estimated from a Kaplan Meier plot of OS at the time of the primary analysis.
Time frame: From date of surgery until date of death due to any cause. Assessed at 5 years.
Patterns of Relapse
Relapse was defined as disease recurrence at any site.
Time frame: Within 10 years after surgery
Perioperative Complication rate
Complications after the surgery
Time frame: Within 6 months after surgery
Started Mar 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences →